Cipla announces Q1 FY19 results

Mumbai, August 08, 2018: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited

• consolidated financial results for quarter ended June 30, 2018.
• Financials: Strong YoY sales growth of 12% with EBITDA growing by 12%
  R&D investments at ~INR 278cr / ~7% of sales
• Continued growth momentum: Strong growth across India (+22% YoY), South Africa
  (+14% YoY adjusted for animal health) and API business (+48% YoY)
• Key differentiated launches in the US including Isoproterenol HCI Injection and
  Testosterone Cypionate Injection
• Quality Focus: Received EIR for Goa & Indore Plants

Readmore

Corporate Comm India(CCI Newswire)